Our world-class management team has significant experience in immuno-oncology and in advancing products from early stage research to clinical trials, and ultimately to regulatory approval and commercialization.

Our current executive officers and directors are listed below. We have also formed a scientific advisory board that helps guide our research and development programs.

Scott A. Waldman, MD, PhD, FCP, FNAI

Principal Investigator

Dr. Waldman’s career has focused on integrating basic, translational, and clinical research in transmembrane signaling to advance laboratory discovery into patients.



Chris Kim, JD, LL.M., SJD (c)

Chief Executive Officer, Chairman and Managing Manager

Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas.



Harry A. Arena, MBA

Board Member

Mr. Arena was co-founder of Targeted Diagnostics & Therapeutics, Inc., a company focused on developing advanced technologies for use in the diagnosis and treatment of colorectal cancer and other gastrointestinal diseases.